GlassScriptPhysician profile
Meagan E Hinch
NPI 1477901379
$2,384.26
in general payments reported to CMS, 2019-2025
22 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $918 · 2023: $415 · 2024: $392 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $484.85 | 2021-2025 | |
| Pfizer INC. | $263.48 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $235.68 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $213.68 | 2022-2025 | Watchman Flx, Watchman |
| Alnylam Pharmaceuticals INC. | $209.34 | 2022-2024 | Onpattro |
| Merck Sharp & Dohme LLC | $188.15 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $166.49 | 2021-2022 | |
| Esperion Therapeutics, INC. | $152.20 | 2021-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.82 | 2021-2025 | Jardiance |
| Silk Road Medical, INC. | $49.64 | 2021-2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Astrazeneca Pharmaceuticals LP | $43.64 | 2021-2024 | Farxiga |
| Lexicon Pharmaceuticals, INC. | $37.34 | 2023 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.79 | 2023 | Lifevest |
| Novo Nordisk INC | $36.72 | 2025 | Wegovy, Ozempic |
| Amarin Pharma, INC. | $31.46 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $27.67 | 2025 | Assure Wcd |
| Scpharmaceuticals INC. | $21.38 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.01 | 2022 | |
| Abbott Laboratories | $20.65 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $16.77 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $14.81 | 2024 | Arcalyst |
| Amgen INC. | $14.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Hinch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.